P53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Andreotti, Virginia ^a   Ciribilli, Yari ^b   Monti, Paola ^a   Bisio, Alessandra ^b   Lion, Mattia ^b   Jordan, Jennifer ^b   Fronza, Gilberto ^a   Menichini, Paola ^a   Resnick, Michael A ^c   Inga, Alberto ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TRENTO   (Italy)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; GALACTOSE; NUTLIN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RITA; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; RENILLA LUCIFERIN 2 MONOOXYGENASE; SIGNAL PEPTIDE; TP53BP1 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; ENZYME ASSAY; FUNGAL STRAIN; HIGH THROUGHPUT SCREENING; MISSENSE MUTATION; NONHUMAN; PROCESS DEVELOPMENT; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SCREENING TEST; TRANSACTIVATION; WILD TYPE; ANIMAL; DNA RESPONSIVE ELEMENT; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MUTATION; REPORTER GENE; SACCHAROMYCES CEREVISIAE; TRANSCRIPTION INITIATION;

ANIMALS; GENES, REPORTER; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUCIFERASES, RENILLA; MUTATION; PROTO-ONCOGENE PROTEINS C-MDM2; RESPONSE ELEMENTS; SACCHAROMYCES CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957943505     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020643     Document Type: Article

References (84)

1. Riley T, Sontag E, Chen P, Levine A, (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol pp. 402-412.
2. Menendez D, Inga A, Resnick MA, (2009) The expanding universe of p53 targets. Nature Rev Cancer 9: 724-737.
3. Lane D, Levine A, (2010) p53 Research: The Past Thirty Years and the Next Thirty Years. Cold Spring Harb Perspect Biol 2: a000893.
4. Vousden KH, Ryan KM, (2009) p53 and metabolism. Nat Rev Cancer 9: 691-700.
5. Gottlieb E, Vousden KH, (2010) p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2: a001040.
6. Perry ME, (2010) The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb Perspect Biol 2: a000968.
7. Olivier M, Hollstein M, Hainaut P, (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2: a001008.
8. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, et al. (2005) Temporal dissection of p53 function in vitro and in vivo. Nat Genet 37: 718-726.
9. Kastan MB, (2007) Wild-type p53: tumors can't stand it. Cell 128: 837-840.
10. Farnebo M, Bykov VJ, Wiman KG, (2010) The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 396: 85-89.
11. Xue W, Zender L, Miething C, Dickins RA, Hernando E, et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
12. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
13. Blagosklonny MV, el-Deiry WS, (1996) In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer 67: 386-392.
14. Foster BA, Coffey HA, Morin MJ, Rastinejad F, (1999) Pharmacological rescue of mutant p53 conformation and function [see comments]. Science 286: 2507-2510.
15. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, et al. (1999) A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy. Science 285: 1733-1737.
16. Michael D, Oren M, (2002) The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 12: 53-59.
17. Toledo F, Wahl GM, (2007) MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol pp. 1476-1482.
18. Toledo F, Wahl GM, (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer pp. 909-923.
19. Kaustov L, Lukin J, Lemak A, Duan S, Ho M, et al. (2007) The conserved CPH domains of Cul7 and PARC are protein-protein interaction modules that bind the tetramerization domain of p53. J Biol Chem pp. 11300-11307.
20. Montes de Oca Luna R, Wagner DS, Lozano G, (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
21. Eischen CM, Lozano G, (2009) p53 and MDM2: antagonists or partners in crime? Cancer Cell 15: 161-162.
22. Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Medeiros LJ, et al. (2007) HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol 20: 54-62.
23. Valentin-Vega YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G, (2007) High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol 38: 1553-1562.
24. Arkin MR, Wells JA, (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3: 301-317.
25. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, et al. (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10: 1321-1328.
26. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
27. Sun SH, Zheng M, Ding K, Wang S, Sun Y, (2008) A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Biol Ther 7: 845-852.
28. Popowicz GM, Czarna A, Holak TA, (2008) Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 7: 2441-2443.
29. Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, et al. (2008) Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther 7: 1533-1542.
30. Resnick MA, Inga A, (2003) Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci U S A 100: 9934-9939. Epub 2003 Aug 9938.
31. Jordan JJ, Menendez D, Inga A, Nourredine M, Bell D, et al. (2008) Noncanonical DNA motifs as transactivation targets by wild type and mutant p53. PLoS Genet 4: e1000104.
32. Tomso DJ, Inga A, Menendez D, Pittman GS, Campbell MR, et al. (2005) Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc Natl Acad Sci U S A 102: 6431-6436.
33. Jegga AG, Inga A, Menendez D, Aronow BJ, Resnick MA, (2008) Functional evolution of the p53 regulatory network through its target response elements. Proc Natl Acad Sci U S A 105: 944-949.
34. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, et al. (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3: 632-638.
35. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, et al. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282-288.
36. Wiman KG, (2010) Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29: 4245-4252.
37. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737.
38. Inga A, Storici F, Darden TA, Resnick MA, (2002) Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 22: 8612-8625.
39. Stepanov A, Nitiss KC, Neale G, Nitiss JL, (2008) Enhancing drug accumulation in Saccharomyces cerevisiae by repression of pleiotropic drug resistance genes with chimeric transcription repressors. Mol Pharmacol 74: 423-431.
40. Storici F, Resnick MA, (2006) The delitto perfetto approach to in vivo site-directed mutagenesis and chromosome rearrangements with synthetic oligonucleotides in yeast. Methods Enzymol 409: 329-345.
41. Storici F, Durham CL, Gordenin DA, Resnick MA, (2003) Chromosomal site-specific double-strand breaks are efficiently targeted for repair by oligonucleotides in yeast. Proc Natl Acad Sci U S A 100: 14994-14999.
42. Kolodkin AL, Klar AJ, Stahl FW, (1986) Double-strand breaks can initiate meiotic recombination in S. cerevisiae. Cell 46: 733-740.
43. Tran HT, Keen JD, Kricker M, Resnick MA, Gordenin DA, (1997) Hypermutability of homonucleotide runs in mismatch repair and DNA polymerase proofreading yeast mutants. Mol Cell Biol 17: 2859-2865.
44. Meyers S, Schauer W, Balzi E, Wagner M, Goffeau A, et al. (1992) Interaction of the yeast pleiotropic drug resistance genes PDR1 and PDR5. Curr Genet 21: 431-436.
45. Reamon-Buettner SM, Ciribilli Y, Traverso I, Kuhls B, Inga A, et al. (2009) A functional genetic study identifies HAND1 mutations in septation defects of the human heart. Hum Mol Genet 18: 3567-3578.
46. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, et al. (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 92: 3963-3967.
47. Inga A, Monti P, Fronza G, Darden T, Resnick MA, (2001) p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene 20: 501-513.
48. Golin J, Ambudkar SV, Gottesman MM, Habib AD, Sczepanski J, et al. (2003) Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux. J Biol Chem 278: 5963-5969.
49. Mitterbauer R, Weindorfer H, Safaie N, Krska R, Lemmens M, et al. (2003) A sensitive and inexpensive yeast bioassay for the mycotoxin zearalenone and other compounds with estrogenic activity. Appl Environ Microbiol 69: 805-811.
50. Freedman DA, Wu L, Levine AJ, (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55: 96-107.
51. Wang T, Kobayashi T, Takimoto R, Denes AE, Snyder EL, et al. (2001) hADA3 is required for p53 activity. Embo J 20: 6404-6413.
52. Alarcon-Vargas D, Ronai Z, (2002) p53-Mdm2-the affair that never ends. Carcinogenesis 23: 541-547.
53. Chao C, Saito S, Anderson CW, Appella E, Xu Y, (2000) Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc Natl Acad Sci U S A 97: 11936-11941.
54. Dumaz N, Meek DW, (1999) Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. Embo J 18: 7002-7010.
55. Gasch AP, Spellman PT, Kao CM, Carmel-Harel O, Eisen MB, et al. (2000) Genomic expression programs in the response of yeast cells to environmental changes. Mol Biol Cell 11: 4241-4257.
56. Di Ventura B, Funaya C, Antony C, Knop M, Serrano L, (2008) Reconstitution of Mdm2-dependent post-translational modifications of p53 in yeast. PLoS One 3: e1507.
57. Ward IM, Minn K, van Deursen J, Chen J, (2003) p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol 23: 2556-2563.
58. Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S, (1994) Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci U S A 91: 6098-6102.
59. Selivanova G, (2010) Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 20: 46-56.
60. Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, et al. (2009) Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 15: 441-453.
61. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, et al. (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15: 376-388.
62. Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, et al. (2010) The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 17: 982-989.
63. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
64. FitzGerald JE, Grenon M, Lowndes NF, (2009) 53BP1: function and mechanisms of focal recruitment. Biochem Soc Trans 37: 897-904.
65. Shibata A, Barton O, Noon AT, Dahm K, Deckbar D, et al. (2010) Role of ATM and the damage response mediator proteins 53BP1 and MDC1 in the maintenance of G(2)/M checkpoint arrest. Mol Cell Biol 30: 3371-3383.
66. Cao L, Xu X, Bunting SF, Liu J, Wang RH, et al. (2009) A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell 35: 534-541.
67. Derbyshire DJ, Basu BP, Serpell LC, Joo WS, Date T, et al. (2002) Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. Embo J 21: 3863-3872.
68. Kachirskaia I, Shi X, Yamaguchi H, Tanoue K, Wen H, et al. (2008) Role for 53BP1 Tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling. J Biol Chem 283: 34660-34666.
69. Roy S, Musselman CA, Kachirskaia I, Hayashi R, Glass KC, et al. (2010) Structural insight into p53 recognition by the 53BP1 tandem Tudor domain. J Mol Biol 398: 489-496.
70. LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, et al. (2007) Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res 67: 450-454.
71. Bykov VJ, Issaeva N, Selivanova G, Wiman KG, (2002) Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23: 2011-2018.
72. Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, et al. (2005) Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res 7: R765-774.
73. Russo D, Ottaggio L, Penna I, Foggetti G, Fronza G, et al. (2010) PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells. Biochem Biophys Res Commun 402: 345-350.
74. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463: 501-506.
75. Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, et al. (2009) HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res 69: 6241-6248.
76. Coutinho I, Pereira C, Pereira G, Goncalves J, Corte-Real M, et al. (2011) Distinct regulation of p53-mediated apoptosis by protein kinase Calpha, delta, epsilon and zeta: Evidence in yeast for transcription-dependent and-independent p53 apoptotic mechanisms. Exp Cell Res.
77. Coutinho I, Pereira G, Leao M, Goncalves J, Corte-Real M, et al. (2009) Differential regulation of p53 function by protein kinase C isoforms revealed by a yeast cell system. FEBS Lett 583: 3582-3588.
78. Inga A, Resnick MA, (2001) Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Oncogene 20: 3409-3419.
79. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M, (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26: 2157-2165.
80. Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, et al. (1997) Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A 94: 14338-14342.
81. Kato S, Han SY, Liu W, Otsuka K, Shibata H, et al. (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100: 8424-8429.
82. Shakked Z, (2007) Quaternary structure of p53: the light at the end of the tunnel. Proc Natl Acad Sci U S A 104: 12231-12232.
83. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, et al. (2006) Structural basis of DNA recognition by p53 tetramers. Mol Cell 22: 741-753.
84. Kitayner M, Rozenberg H, Rohs R, Suad O, Rabinovich D, et al. (2010) Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. Nat Struct Mol Biol 17: 423-429.